A new fixed effects model finds that larger firms pay between 11 and 20 percent higher wages than small firms.

Nations with businesses that spend more on R&D experience fewer firm closures. As such, policymakers should incentivize domestic businesses to invest more in R&D if they want to see industries succeed and grow, boosting the overall economy.

President Trump’s proposal to move USPS under the Department of Commerce would politicize an independent institution, risking service disruptions and unfair pricing. Instead, USPS needs innovation-focused reforms that boost efficiency, strengthen public-private collaboration, and maintain its universal service mission without political interference.

An ITIF model shows how foreign retaliation to tariffs announced by the Trump administration would reduce U.S. exports of the advance manufactured goods covered under the WTO’s Information Technology Agreement.

If states or NTIA plan to spend tens of thousands of dollars per home on deployment and thereby deny affordability support to millions, they should be prepared to explain why they’re spending most or all their money on 3 percent of the problem.

With the right infrastructure and vision, the United States can become a global leader in AI-enabled diplomacy. The State Department should seize this moment—not just to experiment with AI and increase organizational efficiency, but to embed AI at the core of how it conducts diplomacy in the 21st century.

The higher education sector remains the leader in R&D investments for basic research. If the United States wants to stay ahead of China, it must invest more, not less, in basic and applied research to build the foundational knowledge needed for innovation.

To beat China, the United States must better align university research with critical technologies and ensure it directly supports the needs of American firms. To do that, federal research funding agencies should prioritize university researchers who have secured financial commitments from industry.

The United States shoulders the cost of global drug innovation—unless wealthy nations pay their fair share, future cures will stall.

Trump is right to confront unfair trade—but without strategic focus and allied cooperation, his tariffs risk handing the global economy to China.